Description: BetterLife Pharma Inc., a biotechnology company, primarily focuses on developing compounds for the treatment of mental disorders in Canada. It is also involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight viral infections. The company's products pipeline includes BETR-001 for the treatment of major depressive disorder, anxiety, and neuropathic pain and other neuro-psychiatric and neurological disorders; and BETR-002 to treat benzodiazepine dependency, anxiety, and neurodegenerative disorders. It is also developing MM-003, which has completed Phase II clinical trials for the treatment of COVID-19 and other respiratory viral infections; and MM-001, a topical cream that has completed Phase II clinical trials for local intravaginal use to treat HPV-induced cervical intraepithelial neoplasia. The company was formerly known as Pivot Pharmaceuticals Inc. and changed its name to BetterLife Pharma Inc. in December 2019. BetterLife Pharma Inc. was incorporated in 2002 and is headquartered in Vancouver, Canada.
Home Page: www.abetterlifepharma.com
1275 West 6th Avenue
Vancouver,
BC
V6H 1A6
Canada
Phone:
604 221 0595
Officers
Name | Title |
---|---|
Dr. Ahmad Doroudian Ph.D. | Founder, CEO & Chairman |
Ms. Moira Ong C.A., CPA, CA, CFA | Chief Financial Officer |
Dr. Hooshmand Sheshbaradaran Ph.D. | Chief Operating Officer |
Dr. Stephen Sangha | Corporate Development Advisor |
Mr. Scott Rudge Ph.D. | Head of CMC |
Anthony Calandra Ph.D. | Head of Regulatory |
Dr. Abdi Ghaffari Ph.D. | Head of Preclinical & Toxicology |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
GIC Sector: | Health Care |
---|---|
GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
GIC Industry: | Biotechnology |
GIC Sub-Industry: | Biotechnology |
Forward PE: | 0 |
---|---|
Trailing PE: | 0 |
Price-to-Book MRQ: | 12.4106 |
Price-to-Sales TTM: | 0 |
IPO Date: | |
Fiscal Year End: | January |
Full Time Employees: | 0 |